Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
A significant proportion of colorectal cancer (CRC) patients are resistant to anti-ERBB1 [avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, receptor for EGF] monoclonal antibodies (Mabs). We evaluated both immune and nonimmune effects of cetuximab (anti-ERBB1 Mab), trastuzumab (anti-ERBB2 Mab), pertuzumab (anti-ERBB2 Mab), and lapatinib (dual ERBB1 and ERBB2 tyrosine kinase inhibitor) in a large well-characterized panel of 64 CRC cell lines to find response predictive tumor characteristics. There was a significant correlation between the direct effects of cetuximab and lapatinib. Both agents were associated ( P = 0.0004) with “triple’ wild-type status in KRAS , BRAF , and PIK3CA exon 20 . Most cell lines were resistant to the direct effects of anti-ERBB2 Mabs, suggesting that the effects of lapatinib might mainly be through ERBB1. Microarray mRNA expression profiles of sensitive and resistant cell lines showed that although ERBB1 receptor or ligand levels did not associate with cetuximab sensitivity, high levels of ERBB2 ( P = 0.036) and amphiregulin ( P = 0.026) predicted sensitivity to lapatinib. However, higher ERBB1 expression predicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred independently of KRAS/BRAF/PIK3CA mutations ( P = 0.69). Lapatinib may be an effective alternative therapy to cetuximab in triple wild-type tumors. Microarray analysis provides suggestive biomarkers for resistance. ERBB1 levels, independent of mutation status, predict immune killing. Therefore, anti-ERBB1 antibodies may be considered in CRC tumors with higher ERBB1 expression and favorable FcγR polymorphisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 5×
“The overall data thus clearly support the use of KRAS, BRAF, and PIK3CA exon 20 profiling for predicting responses to anti-ERBB1 therapy (7, 9, 23).”
BackgroundMethodResultInfluentialUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 1×
“BRAF V600E mutation has been associated with poor clinical outcome but has not yet been shown to be strongly predictive of clinical response to cetuximab and FOLFIRI (2).”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 2×
“Previous in vitro studies have shown that BRAF V600E mutant cell lines (HT29 and COLO205) are resistant to cetuximab treatment (23, 24).”
BackgroundMethodChung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 1×
“It has been shown that engineering the hinge region of antibodies can greatly enhance immune-mediated killing (14, 15, 32).”
BackgroundSartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · cited 3×
“The relative contributions of immune [for example antibodydependant cellular cytotoxicity (ADCC) and antibody-dependant cellular phagocytosis (ADCP)] and nonimmune processes (competitive blocking of receptor-ligand binding) to tumor response following antibody therapy are not yet clear (5, 6).”
BackgroundJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 2×
“However, all but one of these cell lines also had concomitant mutations in KRAS or BRAF, making it difficult to conclude what impact a PIK3CA exon 20 mutation alone has on resistance (20).”
BackgroundResultJacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368 · cited 2×
“Reports have suggested that AREG and EREG levels may predict cetuximab response (13, 25).”
BackgroundPrenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2017 · Cited by 110 · cited 4×
“There are conflicting clinical reports regarding the influence of ERBB1 receptor expression in tumor response to anti-ERBB1 antibodies (12, 27, 28).”
BackgroundInfluentialPTEN status in advanced colorectal cancer treated with cetuximab
Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., Pedrazzi, G., & Ardizzoni, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605471 · Cited by 83
Cited by
Epigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 910
CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
Eide, P. W., Bruun, J., Lothe, R. A., & Sveen, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-16747-x · Cited by 437
Cancer Cell Lines for Drug Discovery and Development
Wilding, J. L., & Bodmer, W. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2971 · Cited by 432
“For colorectal cancer, these include mutations in the genes APC, TP53, CTNNB1, BRAF, PIK3CA, and FBXW7, and the mismatch repair genes, mainly MLH1 and MSH2.”
BackgroundInfluentialSelf-citationMouradov, D., Sloggett, C., Jorissen, R. N., Love, C. G., Li, S., Burgess, A. W., Arango, D., Strausberg, R. L., Buchanan, D., Wormald, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0013 · Cited by 375
Self-citationSchütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Metadata
- Authors
- Ashraf, S. Q., Nicholls, A. M., Wilding, J. L., Ntouroupi, T. G., Mortensen, N. J., & Bodmer, W. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-12-03
- Volume
- 109
- Issue
- 51
- Pages
- 21046-21051
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1966067305
- Cited by
- 47
- References
- 16
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.